You just read:

Janssen Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis

News provided by

Janssen Biotech, Inc.

Nov 17, 2016, 08:00 ET